NeuroVasx, Inc. has announced that the first procedure in Spain utilizing its cPAX Aneurysm Treatment System was performed in Madrid. cPAX received CE Mark earlier this year. The cPAX System is a minimally invasive device for the embolization of cerebral aneurysms, abnormal bulges or sacs in the wall of an artery in the brain. If ruptured, aneurysms can result in massive intracranial bleeding and often lead to death.

For the full story, click here

Medtronic Inc announced the approval of its Attain Ability left-heart lead (Model 4196) by the U.S. Food and Drug Administration (FDA) for use with cardiac resynchronization therapy (CRT) devices for heart failure patients. Attain Ability has the thinnest lead body of any left-heart lead currently available, providing physicians with a tool to deliver therapy directly to hard-to-reach areas of the heart.

SiDMAP, LLC, has expanded its SiDTox™ services to enable rapid and specific detection of drug-induced organ toxicity. Using its proprietary metabolomics technology platform, SiDMAP is able to monitor changes in vital metabolite fluxes in response to drug treatment to quickly determine organ toxicity before structural or morphological damage occurs. On the basis of a research performed by SiDMAP along with the Center for Metabolomics at the FDA National Center for Toxicological Research, SiDTox™ will now include an affordable and non-invasive test that will allow researchers to detect drug-induced toxicity before organ damage.